Previous 10 | Next 10 |
Exelixis, Inc. (EXEL) Barclays Global Healthcare Conference 2020 March 10, 2020 03:50 PM ET Company Participants Mike Morrissey - Chief Executive Officer Conference Call Participants Peter Lawson - Barclays Presentation Peter Lawson Good afternoon. Welcome to Barclays...
Who doesn't love a good sale? With the markets in turmoil and little idea when it will end, healthcare investors can seize the opportunity to snap up discounted shares of quality companies. Here, I explore six attractive small and mid-cap biotechs with valuations greater than $5.5 billion. Thes...
The Magic Formula by Joel Greenblatt has been a subject of my writing in the past . What used to bug me is that the screen included many microcaps and odd stocks such as royalty trusts. Therefore I decided to set the minimum market cap at $2.5bn. Overall, I am pleased with the new result be...
The following slide deck was published by Exelixis, Inc. in conjunction with their 2019 Q4 earnings Read more ...
I last covered Exelixis ( EXEL ) in May 2018 . Since then, much has changed for the pharmaceutical industry as well as the company. Despite this, Exelixis continues to be an attractive pick in 2020. Company overview Exelixis is an oncology-focused biotechnology company with a market c...
SmileDirectClub (NASDAQ: SDC ) -24% on Q4 earnings . More news on: SmileDirectClub, Inc., Spherix Incorporated, Fossil Group, Inc., Stocks on the move, , Read more ...
Image source: The Motley Fool. Exelixis Inc (NASDAQ: EXEL) Q4 2019 Earnings Call Feb 25, 2020 , 5:00 p.m. ET Operator Continue reading
Exelixis, Inc. (EXEL) Q4 2019 Earnings Conference Call February 25, 2020, 17:00 ET Company Participants Susan Hubbard - EVP, Public Affairs & IR Michael Morrissey - CEO, President & Director Patrick Haley - EVP, Commercial Christopher Senner - EVP & CFO Gisela Sch...
Exelixis (NASDAQ: EXEL ) reports mixed Q4 results that beat on EPS and missed on revenue. The company guides in-line FY revenue of $850-900M (consensus: $934.42M). More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Exelixis (NASDAQ: EXEL ): Q4 Non-GAAP EPS of $0.26 beats by $0.05 ; GAAP EPS of $0.22 beats by $0.05 . Revenue of $240.3M (+5.1% Y/Y) misses by $3.39M . Shares -1.5% . Press Release More news on: Exelixis, Inc., Earnings news and commentary, Healthcare stocks news,
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...